Journal
VACCINE
Volume 31, Issue 12, Pages 1553-1559Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2013.01.025
Keywords
Antiviral immunity; Serum therapy; Monoclonal antibody; Antibody engineering
Categories
Ask authors/readers for more resources
Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable. Crown Copyright (c) 2013 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available